Neuralink Corporation, a private company specializing in brain-computer interfaces, has not yet gone public, and its shares are not available on any stock exchange. Following a $650 million Series E funding round in June 2025, the company's valuation stands at approximately $9.65 billion, with a per-share price estimated at $240.03 as of August 25, 2026.
The absence of a public stock ticker and no announced IPO date means that Neuralink remains a private entity, with no SEC filings indicating a move toward public trading. The company's innovative technology, including the N1 chip and its application in clinical trials, highlights its potential impact on the medical field, particularly for individuals with paralysis.
As Neuralink continues its PRIME clinical trial, which has enrolled 26 patients globally, the results from its two-year study show promising advancements in neural decoding speeds. Investors and stakeholders should monitor any developments regarding a potential IPO, as no timeline has been disclosed at this time.
Editor's Note
Neuralink's ongoing clinical trials and advancements in brain-computer interface technology position it at the forefront of medical innovation. As the company navigates its path toward a potential IPO, industry stakeholders should consider the implications of its technology on healthcare and investment opportunities. The lack of public trading options currently limits retail investor access, making secondary market platforms crucial for those interested in Neuralink's valuation.
Leave a comment